Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 8, Pages 1367-1373
Publisher
Springer Nature
Online
2012-03-28
DOI
10.1038/bjc.2012.85
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
- (2010) Nadia Margariti et al. BREAST CANCER RESEARCH AND TREATMENT
- Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
- (2010) Rita Nahta et al. Clinical Breast Cancer
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma
- (2010) Gloria Peiró et al. MODERN PATHOLOGY
- MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
- (2009) Shawn P. Fessler et al. BREAST CANCER RESEARCH AND TREATMENT
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
- (2009) E. Yao et al. CLINICAL CANCER RESEARCH
- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
- (2008) M. Untch et al. ANNALS OF ONCOLOGY
- Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma
- (2008) Gloria Peiró et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Targeted therapies in breast cancer: Where are we now?
- (2008) Serena Di Cosimo et al. EUROPEAN JOURNAL OF CANCER
- Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
- (2008) Paul L. Nguyen et al. JOURNAL OF CLINICAL ONCOLOGY
- A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells
- (2008) Sanjeev Mahanta et al. PLoS One
- MUC1* Mediates the Growth of Human Pluripotent Stem Cells
- (2008) Sherry T. Hikita et al. PLoS One
- Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
- (2008) Enrique Lerma et al. VIRCHOWS ARCHIV
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started